Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
0
Authors
Michael Wang
Michael Wang•Kristie Blum•Simon Rule
Published
June 9, 2015
Abstract
Key Points Ibrutinib demonstrates durable responses and sustained single-agent activity in relapsed or refractory MCL at median 26.7-month follow-up. Ibrutinib shows a favorable benefit-risk profile over time, with a manageable safety profile.
